BSE 659.10 NSE 658.75
BSE 659.10 NSE 658.75

Spiro Gavaris

President U.S. Generics Business

Spiro is responsible for the overall strategy, implementation, and growth of Lupin’s U.S. Generics Business.

Prior to joining Lupin, he gained comprehensive pharma, injectables and biotech experience, most notably serving as the President, Specialty Generics at Mallinckrodt Pharmaceuticals and President, US Injectables at Hikma.

Spiro holds a Bachelor’s degree from Franklin & Marshall College and MBA from New York University Stern School of Business.

 Download Profile